SOPHiA GENETICS SA

Equities

SOPH

CH1125843347

Software

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
4.99 USD -1.48% Intraday chart for SOPHiA GENETICS SA +5.50% +5.94%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Fall Late Afternoon MT
Sophia Genetics Rallies Wednesday after Partnering with Microsoft, Nvidia on Whole Genome Analytics Platform MT
SOPHiA GENETICS SA to Launch New Whole Genome Sequencing Capabilities CI
SOPHiA GENETICS Announces Instituto Mário Penna as New Customer CI
Transcript : SOPHiA GENETICS SA, Q1 2024 Earnings Call, May 07, 2024
SOPHiA GENETICS SA Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
SOPHiA GENETICS Reiterates Earnings Guidance for the Full Year 2024 CI
Sophia Genetics Says Nigeria's Syndicate Bio Signs on to Implement Liquid Biopsy Offering MT
SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa CI
SOPHiA GENETICS Announces Unilabs Using Its AI Technology to Detect Homologous Recombination Deficiency CI
Sophia Genetics Forms Partnership With Strand Life Sciences to Advance Diagnostic Tools MT
Sophia Genetics SA Announces Laboratorio Barnafi-Krause Is Live on the Sophia DDM? Platform CI
SOPHiA GENETICS Announces First Homologous Recombination Deficiency Customer in Canada CI
Transcript : SOPHiA GENETICS SA Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 through Mar-14-2024
Transcript : SOPHiA GENETICS SA, Q4 2023 Earnings Call, Mar 05, 2024
SOPHiA GENETICS SA Provides Earnings Guidance for 2024 CI
SOPHiA GENETICS SA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : S&P 500 Futures -2- DJ
Sophia Genetics, AstraZeneca Expand Project to Improve Access to Ovarian Cancer Testing in Spain MT
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain CI
Sophia Genetics Supports Genetic Testing in Brazil CI
SOPHiA GENETICS Enhances RareCyte Inc. Precision Biology Services Portfolio CI
SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India CI
Transcript : SOPHiA GENETICS SA Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:00 AM
SOPHiA GENETICS SA Provides Preliminary Earnings Guidance for the Full Year Ending December 31, 2023 CI
Chart SOPHiA GENETICS SA
More charts
Sophia Genetics SA is a Switzerland-based company engaged in the software publishing sector. The Company offer a cloud-based Software-as-a-Service platform - the SOPHiA DDM, which is data-driven medicine platform enabling insights from disparate, complex datasets to improve diagnosis, treatment, and drug development. The Company has offices in Switzerland, France and the United Kingdom and operates worldwide.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.99 USD
Average target price
8.667 USD
Spread / Average Target
+73.68%
Consensus
  1. Stock Market
  2. Equities
  3. SOPH Stock
  4. News SOPHiA GENETICS SA
  5. SOPHiA GENETICS : JPMorgan Starts SOPHiA GENETICS at Overweight With $23 Price Target